Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.7.0.1
Commitments and Contingencies (Details)
Dec. 31, 2016
USD ($)
Commencement Of Phase II Study For a Licensed Product [Member]  
Commitments and Contingencies [Line Items]  
Milestone Payments Liabilities $ 200,000
Commencement Of Phase III Study For a Licensed Product [Member]  
Commitments and Contingencies [Line Items]  
Milestone Payments Liabilities 250,000
Filing Of a New Drug Application For a Licensed Product [Member]  
Commitments and Contingencies [Line Items]  
Milestone Payments Liabilities 400,000
Receipt Of Market Approval For a Licensed Product [Member]  
Commitments and Contingencies [Line Items]  
Milestone Payments Liabilities $ 500,000